.svg){kind=small}
Reduce your recruitment timelines
Using our efficient recruitment techniques, adaptive study designs and integrated protocols we can run hybrid studies reducing our sponsors’ drug development time.
Examples of our accelerated recruitment
Accurate costs projection. We conducted a FIH study of Lumasiran in March 2016. Our team helped to accelerate drug development using adaptive study design and provide accurate cost projections through efficient recruitment. Alnylam received marketing authorisation in April 2020.
In a study for Symptomatic Transthyretin Amyloid Cardiomyopathy, Richmond Pharmacology enrolled 11% of patients in a multi-centre study involving 104 global centres.
Reliability and operational scalability. Our in-house recruitment team enrolled 92 hypertensive patients for a global study on behalf of Alnylam, fulfilling 58% of the total cohort. Our patient networks enabled us to rapidly upscale recruitment and reduce the study timelines.
We enable rapid drug development
By swiftly adapting strategies to suit the unique demands of individual trials, we ensure resources are invested in the most appropriate recruitment tactics. Frequently recruiting more than our allotted cohort size in multi-centre studies, we enable our sponsors to complete enrolment early.
We are renowned for our recruitment capabilities.
Our dedicated in-house recruitment team delivers a personal service ensuring volunteers are engaged from the first contact to the last appointment.
Why choose Richmond Pharmacology for Patient Recruitment in Early Phase Studies
Accurate timeline and cost predictability
We offer invaluable insight into study acceptability and suitability.
Read more +Volunteer experience
By listening to the feedback of our volunteers, we make continuous improvements to the experience of our research participants.
Hear from our sponsors
.svg){kind=small}
-min.jpg)
.jpg)
Latest news
Futureproofing early phase clinical research for the next generation of investigators.
Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.
Events
13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions
